The firm envisions applying its new PlexSet technology to the upper end of multiplex gene expression analysis as well as CRISPR validation applications.
CEO Brad Gray said the firm has outgrown its existing sales model and will be looking to add both new sales leadership and new consumables sales roles.
The company saw growth in almost all parts of its revenue stream, except instruments, including a 69 percent increase in revenue from collaborations.
NanoString said its sequencing technology harnesses its expertise in optical barcodes and that it would develop it for clinical use to complement its existing products.
The GenomeWeb Index rose more than 6 percent in January, outperforming the Dow, Nasdaq, and Nasdaq Biotechnology Index.
The coverage decision provides Humana's 13 million members with access to the test, which provides a numerical score to assess the risk of disease recurrence.
Executives provided updates on their companies at the 35th Annual JP Morgan Healthcare Conference in San Francisco.
The firm expects full-year revenue growth of up to 39 percent, but fell short of prior guidance for the year.
It was a rough year for biotech stocks — the Nasdaq Biotech Index fell 22 percent even as the Dow gained 13 percent and the Nasdaq gained 8 percent.
The evaluation presented at SABCS last week highlighted the importance of considering node-positive and -negative patients, and incorporating clinical information with molecular tests.
HHS Secretary Tom Price says the NIH budget contains unneeded expenses that can be trimmed, Stat News reports.
The chair of the House science committee says the journal Science is not objective, the Huffington Post reports.
In Nature this week: glioma GWAS uncovers new risk loci, and more.
Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.